Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression

Jimmy M-M Kwok1, Stephen S Myatt, Charles M Marson

  • 1Cancer Research-UK Labs, Department of Oncology, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom.

Insights

The antibiotic thiostrepton targets the forkhead box M1 (FOXM1) transcription factor, selectively killing breast cancer cells. This FOXM1 repression halts cancer cell proliferation, migration, and metastasis with minimal toxicity to normal cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Elevated forkhead box M1 (FOXM1) expression drives breast cancer development and progression.
  • Targeting FOXM1 offers a potential therapeutic strategy for breast cancer.

Purpose of the Study:

  • To investigate the effect of the thiazole antibiotic thiostrepton on FOXM1 expression in breast cancer cells.
  • To determine the therapeutic potential of thiostrepton as a FOXM1-targeting agent for breast cancer.

Main Methods:

  • Treatment of breast cancer cells with thiostrepton.
  • Analysis of FOXM1 expression levels at transcriptional and gene promoter levels.
  • Cell cycle analysis and assessment of apoptosis (caspase-dependent and independent pathways).
  • Evaluation of effects on cell migration, metastasis, and transformation.
  • Experiments with FOXM1 mutant overexpression and non-transformed breast epithelial cells.

Main Results:

  • Thiostrepton selectively down-regulates FOXM1 expression in breast cancer cells in a time- and dose-dependent manner.
  • Thiostrepton induces G1 and S phase cell cycle arrest and cell death via intrinsic/extrinsic apoptotic and caspase-independent pathways.
  • Thiostrepton inhibits breast cancer cell migration, metastasis, and transformation.
  • Overexpression of a FOXM1 mutant abrogates thiostrepton's antiproliferative effects.
  • Thiostrepton shows minimal toxicity against non-transformed breast epithelial cells.

Conclusions:

  • FOXM1 is a primary cellular target of thiostrepton in breast cancer.
  • Thiostrepton effectively represses FOXM1, leading to cell cycle arrest, apoptosis, and inhibition of metastatic phenotypes.
  • Thiostrepton demonstrates potential as a novel, targeted therapeutic agent for breast cancer with a favorable safety profile.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...